Intersect ENT (NASDAQ: XENT) is a medical technology company dedicated to advancing the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, providing physicians with solutions to overcome clinical challenges and improve the quality of life for patients.
Intersect ENTâs initial focus is on improving the treatment of chronic sinusitis, an inflammatory condition that affects one out of eight adults in the U.S. and has a greater impact on quality of life than congestive heart failure or chronic back pain. Chronic sinusitis often requires a complex combination of medical and surgical therapy and is hence one of the most costly conditions to U.S. employers. While traditional surgical solutions relieve symptoms in many patients, disease recurrence is frequent with the majority of patients experiencing recurrent symptoms within the first year.
Intersect ENT is a publicly traded company.
Source
